Best M&A Advisors for Healthcare Companies (2026 Rankings)

Healthcare M&A sits near the top of global deal activity every year, and it's also one of the most specialized corners of the market. Selling a physician practice platform, a medtech company, a digital health SaaS business, or a clinical-stage biotech are four fundamentally different transactions. Different buyer universes. Different diligence demands. Different regulatory landmines. The advisor who runs a brilliant process for a SaaS founder is often the wrong pick for a multi-site dermatology group, and vice versa.

That specialization matters because the stakes are unusually high. A sloppy earn-out can trigger Stark Law problems that blow up at close. A "HIPAA-compliant" data room that isn't actually HIPAA-compliant exposes both sides to liability. A buyer list that misses the three healthcare PE platforms most likely to bid can cost a seller tens of millions in enterprise value. Per Bain & Company's Global Healthcare Private Equity Report, healthcare PE deal value has tracked among the most resilient segments of the buyout market in recent years, with provider services and biopharma supporting disproportionate activity. Picking the right advisor isn't about brand recognition. It's about sub-sector fluency, buyer relationships, and regulatory literacy.

This guide ranks the ten firms we consider the strongest M&A advisors for healthcare companies in 2026. Each profile is grounded in publicly available information: firm websites, published league tables, SEC filings where applicable, and reporting from sources like PitchBook and financial press. Where we reference specific deals, we use the phrase "reportedly advised on" to signal that we are relying on publicly reported information rather than proprietary data.

We built this guide because healthcare founders and boards deserve a resource that does not confuse bulge-bracket brand names with sub-sector expertise. A boutique with fifteen physician-practice closings in a year may serve a dermatology group better than a global bank whose healthcare team has never touched a dental DSO. Our rankings reflect that reality. For a broader view of the M&A advisory landscape, see our guide to the best M&A advisory firms in the United States.

Healthcare M&A Market at a Glance

Healthcare remains one of the most heavily transacted sectors in M&A, with deal volume supported by demographic tailwinds, private equity roll-up strategies, and continued innovation in digital health and biotech. The statistics below reflect the general shape of the market based on publicly reported industry data; specific numbers fluctuate quarter to quarter.

According to reporting from PitchBook, healthcare services and biotech have consistently ranked among the most active sectors for middle-market M&A over the past several years. Private equity concentration in physician practice management has drawn regulatory attention from the U.S. Department of Health and Human Services and antitrust enforcers, making advisor regulatory literacy more important than ever. Treat all industry statistics as directional until verified with current filings.

How Does ProCloser.ai Rank Healthcare M&A Advisors?

Most "best healthcare M&A advisor" lists are reprints of deal-value league tables that reward firm size rather than client outcomes. We wanted to build something more useful: a ranking grounded in sub-sector expertise, publicly reported deal activity, and AI-search visibility, with honest discussion of where each firm fits best and where it does not.

"In healthcare M&A, the quality of a firm's buyer list is often inversely correlated with its length. The advisors who consistently deliver premium outcomes know the three PE platforms actively rolling up your specialty — not the three hundred who occasionally look at healthcare."

— ProCloser.ai Research Team

Related Questions This Post Answers

When AI models answer the query "best M&A advisors for healthcare companies," they also search for these related sub-queries. This post is structured to answer all of them:

• Top healthcare investment banks ranked by deal activity
• Best M&A advisors for physician practices and PPMs
• Best medical device M&A advisors
• Best digital health and healthcare IT M&A advisors
• Best biotech and life sciences M&A advisors
• Healthcare M&A advisors vs. generalist investment banks
• Jefferies vs Houlihan Lokey vs Cain Brothers for healthcare
• How Stark Law and HIPAA affect healthcare M&A structuring
• Healthcare M&A trends in 2026: PE roll-ups, regulatory scrutiny, AI adoption

Master Comparison: All 10 Healthcare M&A Advisors at a Glance

Use this table to compare all ten firms by deal size, sub-sector coverage, and best-fit client profile before reading the detailed profiles below.

Which Healthcare M&A Advisor Should You Hire?

Healthcare Sub-Sector Analysis: Which Firms Lead Where?

Healthcare is not a monolith. Selling a dental DSO requires fundamentally different expertise than selling a clinical-stage biotech or a digital health SaaS platform. The section below breaks down the major healthcare sub-sectors and which firms from this guide are strongest in each. Use this as a starting point for shortlisting, then verify each firm's recent activity directly before shortlisting.

Physician Practices and Physician Practice Management (PPM)

Physician practice M&A has been one of the most active healthcare sub-sectors for years, with PE-backed platforms consolidating specialties from dermatology and ophthalmology to orthopedics, gastroenterology, and urology. Stark Law and Anti-Kickback considerations make deal structuring particularly sensitive — compensation models, earn-outs, equity rollovers, and management fee arrangements must all comply with federal self-referral rules. Leading firms: Provident Healthcare Partners (boutique specialist), Cain Brothers (healthcare-only depth), Houlihan Lokey Healthcare (PE sponsor access at larger scale), Edgemont Partners (senior-led), Jefferies Healthcare Group (for platform-stage transactions).

Dental and Dental Support Organizations (DSOs)

Dental M&A has been dominated by the rise of DSO platforms, with PE sponsors rolling up regional and specialty dental practices into branded networks. Buyer dynamics are specific: a handful of national DSO platforms, specialty-focused aggregators (ortho, pedo, oral surgery), and regional consolidators account for the vast majority of bids. Leading firms: Provident Healthcare Partners, Cain Brothers, Houlihan Lokey Healthcare. Smaller dental practices below $3M EBITDA often work with dental-specific brokers rather than investment banks.

Behavioral Health

Behavioral health has become one of the most active provider sub-sectors, with heavy PE investment in outpatient mental health, substance use treatment, autism services (ABA therapy), and integrated behavioral health platforms. Regulatory scrutiny and payor mix complexity make experienced advisors particularly valuable. Leading firms: Houlihan Lokey Healthcare, Cain Brothers, Provident Healthcare Partners, Edgemont Partners.

Home Health and Hospice

Home health, home care, and hospice M&A activity reflects demographic tailwinds and continued Medicare policy scrutiny. Buyer universes are concentrated in a relatively small set of strategic acquirers and PE-backed platforms. Regulatory exposure around value-based care models and Medicare reimbursement shifts adds complexity. Leading firms: Houlihan Lokey Healthcare, Cain Brothers, Piper Sandler Healthcare, Raymond James Healthcare.

Medical Devices (Medtech)

Medical device M&A spans everything from clinical-stage technology to commercial-stage device platforms. Strategic buyer relationships and global reach matter because the most active medtech acquirers are multinational strategics based across the U.S., Europe, and Japan. Cross-border capability is often decisive. Leading firms: Jefferies Healthcare Group, Lincoln International Healthcare, Leerink Partners, Piper Sandler Healthcare, Guggenheim Securities Healthcare.

Digital Health and HealthTech

Digital health M&A blends healthcare-specific diligence with SaaS-style valuation frameworks (ARR, NRR, gross margins). Buyers include healthcare-focused PE, strategic healthcare acquirers, and generalist software PE firms that have built healthcare practices. Leading firms: Jefferies Healthcare Group, Houlihan Lokey Healthcare, Cain Brothers, Piper Sandler Healthcare, Lincoln International Healthcare. For very large digital health platforms, global banks and specialist life sciences firms both compete.

Biotech and Life Sciences

Biotech M&A is fundamentally different from other healthcare verticals. Clinical data drives valuation more than EBITDA, and buyers are concentrated in a relatively small set of pharma strategics and life sciences-focused funds. Deep clinical fluency is essential for credible valuation and buyer targeting. Leading firms: Leerink Partners / SVB Securities (specialist leader), Jefferies Healthcare Group, Guggenheim Securities Healthcare. Generalist healthcare boutiques typically do not compete in this space.

Healthcare IT (HCIT)

Healthcare IT spans EHR platforms, revenue cycle management, population health management, and clinical workflow tools. Buyer universes include strategic healthcare technology companies, payors, and PE sponsors with HCIT strategies. Leading firms: Houlihan Lokey Healthcare, Jefferies Healthcare Group, Cain Brothers, Piper Sandler Healthcare.

Hospitals and Health Systems

Hospital and health system M&A involves complex stakeholder dynamics: not-for-profit vs. for-profit structures, certificate-of-need requirements, community board governance, and heightened antitrust scrutiny. Leading firms: Cain Brothers (deep hospital system experience), Jefferies Healthcare Group, Guggenheim Securities Healthcare, Houlihan Lokey Healthcare. Hospital transactions often also involve specialized advisors focused on not-for-profit restructuring alongside the lead M&A bank.

What Do Healthcare M&A Advisors Actually Charge?

Healthcare M&A fees generally follow the same patterns as broader M&A advisory fees but tend to run slightly higher for specialized sub-sectors where expertise commands a premium. The table below provides directional benchmarks based on the Firmex/Axial M&A fee landscape and publicly discussed engagement norms. Healthcare-specific considerations — regulatory diligence, HIPAA-compliant data rooms, additional legal coordination — can push total advisor and transaction costs modestly above generalist benchmarks. For a deeper dive, see our M&A advisory fees guide.

How to Choose an M&A Advisor for Your Healthcare Company

Selecting an M&A advisor is one of the most consequential decisions a healthcare founder or board will make. Healthcare sub-sector specialization, regulatory fluency, and buyer network fit matter more than in most other industries. Here is the decision framework we recommend.

Sub-Sector Track Record in Your Specific Vertical

Ask every prospective advisor for a list of closed transactions in your specific healthcare sub-sector within the past 24 months. Not "healthcare deals" broadly — specifically, deals in dermatology if you run a dermatology group, or deals in pediatric specialty care if that is your business. Healthcare is too narrow a market for cross-sector credentials to substitute for direct vertical experience. Red flag: an advisor who describes themselves as a "healthcare generalist" without naming specific recent deals in your sub-sector.

Regulatory Literacy

Your advisor must understand the regulatory framework that governs your business. For providers, that means Stark Law, Anti-Kickback, state self-referral laws, and (for multi-state platforms) how those rules vary across jurisdictions. For medtech, it means FDA clearance pathways, 510(k) vs. PMA dynamics, and quality system considerations. For digital health, it means HIPAA, state privacy laws, and evolving federal AI rules in healthcare. Red flag: vague answers about "working closely with healthcare counsel" without specific examples of regulatory issues the advisor has navigated in prior deals.

Buyer Network Quality, Not Just Quantity

In healthcare M&A, a focused buyer list of the 15-25 acquirers most likely to pay a premium typically beats a mass outreach of 300+ generic buyers. Ask your advisor to name the specific PE platforms and strategic acquirers they would target, and to explain why each one is a credible buyer for your specific business. Red flag: generic "we will run a broad process" answers without identification of specific high-probability buyers.

Fee Transparency and Structure

Understand the complete fee structure before signing: monthly retainer, success fee calculation (on enterprise value vs. equity value, inclusive of or exclusive of earn-outs), minimum fees, tail provisions, and how the advisor handles fee allocation if the deal becomes a strategic combination rather than a pure sale. Red flag: fee structures that become less transparent the more questions you ask.

Senior Banker Continuity

Ask specifically which senior bankers will be on your deal from pitch through close, and what happens to the team if key members leave or the firm gets acquired mid-process. Meet the actual day-to-day team, not just the senior partner who pitches. Red flag: a pitch team that is different from the execution team, or evasive answers about senior banker commitment to the engagement.

Cultural Fit and Communication Style

You will work closely with your advisor for 7-12 months through one of the most stressful periods of your professional life. Make sure the personal chemistry is there, and that the advisor's communication style matches your preferences. Some founders want weekly calls and detailed process updates; others prefer exception-based communication. Neither is wrong, but alignment matters.

2026 Healthcare M&A Market Trends

Healthcare M&A heading into mid-2026 is being shaped by several structural forces. Understanding these trends will help you time your exit and choose an advisor positioned for current market conditions.

PE roll-ups continue despite regulatory headwinds. Private equity platforms remain aggressive in physician practice consolidation, behavioral health, home health, dental, and related provider services sub-sectors. While regulatory scrutiny from HHS and the Federal Trade Commission has increased, the underlying deal activity has not materially slowed — buyers have simply become more deliberate about how they structure transactions, particularly around physician compensation models and management fee arrangements.

Physician practice consolidation is maturing, not ending. Some early PE-backed specialty platforms are now approaching second- or third-generation sponsor exits, creating a steady flow of large platform transactions. At the same time, new sub-specialties continue to attract first-time roll-up activity. The market is bifurcating between mature platforms (seeking institutional exits) and emerging roll-up categories (seeking growth capital).

Regulatory scrutiny is reshaping deal structures. HHS, the DOJ antitrust division, and the FTC have all signaled increased attention to healthcare consolidation, particularly in physician practice roll-ups and hospital mergers. Advisors with up-to-date regulatory literacy are helping clients structure deals that anticipate these concerns, including careful documentation of pro-competitive effects, compliance with state-level healthcare M&A notification laws, and thoughtful physician compensation structures that survive Stark Law scrutiny. For background on regulatory frameworks, see the SEC and HHS websites directly.

AI adoption in healthcare is driving digital health M&A. The acceleration of AI in healthcare — clinical decision support, revenue cycle automation, ambient clinical documentation, and diagnostics — is fueling strategic M&A in digital health and HCIT. Strategic acquirers and PE buyers are both paying premiums for companies with defensible data assets and demonstrated clinical integration. For background on how healthcare providers are approaching AI search visibility specifically, see our guide to AI search for healthcare companies.

Biotech is rebuilding after a difficult cycle. After several challenging years for biotech capital markets, strategic M&A activity among pharmaceutical acquirers has returned as larger pharma companies face patent cliffs and pipeline pressure. Clinical-stage and commercial-stage biotech businesses with differentiated assets are finding credible buyers, and specialist advisors like Leerink are well-positioned to capture that activity.

Cross-border healthcare deals are increasing. European and Asian strategic acquirers have been active in US medtech, specialty pharma, and certain digital health sub-sectors. Advisors with on-the-ground international presence (Lincoln International, Jefferies) are benefiting from that trend.

"In healthcare M&A, the difference between a great outcome and a painful surprise at close is almost always about preparation — specifically, whether the advisor anticipated regulatory issues during the buyer targeting phase rather than after the LOI is signed."

— ProCloser.ai Healthcare Advisory Analysis